150 related articles for article (PubMed ID: 32098948)
21. The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry.
Gonzalez Suarez ML; Zhang P; Nasr SH; Sathick IJ; Kittanamongkolchai W; Kurtin PJ; Alexander MP; Cornell LD; Fidler ME; Grande JP; Herrera Hernandez LP; Said SM; Sethi S; Dispenzieri A; Gertz MA; Leung N
Kidney Int; 2019 Oct; 96(4):1005-1009. PubMed ID: 31447055
[TBL] [Abstract][Full Text] [Related]
22. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.
Wong SW; Hegenbart U; Palladini G; Shah GL; Landau HJ; Warner M; Toskic D; Jaccard A; Hansen T; Bladé J; Cibeira MT; Kastritis E; Dispenzieri A; Wechalekar A; Varga C; Schönland SO; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e493-e499. PubMed ID: 30104177
[TBL] [Abstract][Full Text] [Related]
23. Time to Redefine Risk-Stratification and Response Criteria in Immunoglobulin Light Chain Amyloidosis?
Jain A; Ramasamy K
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e769-e776. PubMed ID: 32653456
[TBL] [Abstract][Full Text] [Related]
24. Clinical presentation and prognosis of immunoglobulin light-chain amyloidosis with high percentage of bone marrow plasma cells.
Zhang CL; Qiu Y; Shen KN; Miao HL; Feng J; Cao XX; Zhang L; Jiang XY; Zhou DB; Li J
Leuk Res; 2019 Jun; 81():19-24. PubMed ID: 30981853
[TBL] [Abstract][Full Text] [Related]
25. Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis.
Landau H; Lahoud O; Devlin S; Lendvai N; Chung DJ; Dogan A; Landgren CO; Giralt S; Hassoun H
Biol Blood Marrow Transplant; 2020 Jan; 26(1):204-208. PubMed ID: 31446197
[TBL] [Abstract][Full Text] [Related]
26. Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy.
Milani P; Basset M; Nuvolone M; Benigna F; Rodigari L; Lavatelli F; Foli A; Merlini G; Palladini G
Blood Cancer J; 2020 Sep; 10(8):90. PubMed ID: 32873771
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
Basset M; Kimmich CR; Schreck N; Krzykalla J; Dittrich T; Veelken K; Goldschmidt H; Seckinger A; Hose D; Jauch A; Müller-Tidow C; Benner A; Hegenbart U; Schönland SO
Br J Haematol; 2021 Oct; 195(2):230-243. PubMed ID: 34341985
[TBL] [Abstract][Full Text] [Related]
28. Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside.
Basset M; Nuvolone M; Palladini G; Merlini G
Expert Rev Hematol; 2020 Sep; 13(9):1003-1015. PubMed ID: 32721177
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of glycation and glycation sites of lysozyme by matrix-assisted laser desorption/ionization time of flight/time-of-flight mass spectrometry and Liquid chromatography-electrospray ionization tandem mass spectrometry.
Ruan ED; Wang H; Ruan Y; Juáreza M
Eur J Mass Spectrom (Chichester); 2014; 20(4):327-36. PubMed ID: 25420345
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis.
Sidana S; Tandon N; Dispenzieri A; Gertz MA; Dingli D; Jevremovic D; Morice WG; Kapoor P; Kourelis TV; Lacy MQ; Hayman SR; Buadi FK; Leung N; Go RS; Lin Y; Russell SJ; Lust JA; Zeldenrust SR; Warsame R; Hwa YL; Hobbs M; Fonder A; Kyle RA; Rajkumar SV; Kumar SK; Gonsalves WI
Leukemia; 2018 Jun; 32(6):1421-1426. PubMed ID: 29483709
[TBL] [Abstract][Full Text] [Related]
31. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.
Ludwig H; Milosavljevic D; Zojer N; Faint JM; Bradwell AR; Hübl W; Harding SJ
Leukemia; 2013 Jan; 27(1):213-9. PubMed ID: 22955329
[TBL] [Abstract][Full Text] [Related]
32. [Detection of abnormal plasma cells in bone marrow contributes to the diagnosis of primary systemic light chain amyloidosis-review].
Hu Y; Zhu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1251-5. PubMed ID: 23114159
[TBL] [Abstract][Full Text] [Related]
33. Biomarkers in AL Amyloidosis.
Fotiou D; Theodorakakou F; Kastritis E
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681575
[TBL] [Abstract][Full Text] [Related]
34. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
35. Red blood cell distribution width is a simple and novel biomarker for survival in light-chain amyloidosis.
Yogo T; Okazuka K; Nashimoto J; Uto Y; Sato K; Miyazaki K; Ogura M; Yoshiki Y; Abe Y; Tsukada N; Ishida T; Suzuki K
Int J Hematol; 2019 Oct; 110(4):431-437. PubMed ID: 31236823
[TBL] [Abstract][Full Text] [Related]
36. Detecting monoclonal immunoglobulins in human serum using mass spectrometry.
Mills JR; Barnidge DR; Murray DL
Methods; 2015 Jun; 81():56-65. PubMed ID: 25916620
[TBL] [Abstract][Full Text] [Related]
37. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.
Sidana S; Larson DP; Greipp PT; He R; McPhail ED; Dispenzieri A; Murray DL; Dasari S; Ansell SM; Muchtar E; Gonsalves WI; Kourelis TV; Ramirez-Alvarado M; Kapoor P; Rajkumar SV; Lacy MQ; Buadi FK; Leung N; Kyle RA; Kumar SK; King RL; Gertz MA
Leukemia; 2020 May; 34(5):1373-1382. PubMed ID: 31780812
[TBL] [Abstract][Full Text] [Related]
38. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue.
Klein CJ; Vrana JA; Theis JD; Dyck PJ; Dyck PJ; Spinner RJ; Mauermann ML; Bergen HR; Zeldenrust SR; Dogan A
Arch Neurol; 2011 Feb; 68(2):195-9. PubMed ID: 20937937
[TBL] [Abstract][Full Text] [Related]
39. Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia.
Buhl AM; James DF; Neuberg D; Jain S; Rassenti LZ; Kipps TJ
Eur J Haematol; 2011 May; 86(5):405-411. PubMed ID: 21323738
[TBL] [Abstract][Full Text] [Related]
40. Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.
Eveillard M; Rustad E; Roshal M; Zhang Y; Ciardiello A; Korde N; Hultcrantz M; Lu S; Shah U; Hassoun H; Smith E; Lesokhin A; Mailankody S; Landgren O; Thoren K
Br J Haematol; 2020 Jun; 189(5):904-907. PubMed ID: 32026474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
